54 results about "Tissue biopsy" patented technology

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention concerns methods for predicting changes in a tissue, comprising obtaining snap shot information on individual cells of at least one cell type in a section of a tissue biopsy, wherein the information comprises: (i) spatial localization, (ii) cell type and (iii) cell division state at a specific point in time; calculating cell division probabilities for each of said individual cells; determining cell population dynamics based on the cell division probabilities and predicting future changes in the tissue based thereon. Particularly, the method concerns predicting tissue dynamics in cancer biopsies relevant for prognosis, and assessment of response to therapy.

The invention discloses a marker for predicting the curative effect of tumor immunotherapy as well as application and a detection method of the marker, and belongs to the technical field of biomedicine. The marker is glycerophosphorylcholine (GPC) in peripheral blood, and under the condition that the GPC level of peripheral plasma is low, it is judged that ICIs immunotherapy is poor in curative effect response. Peripheral blood samples are simple and noninvasive to obtain, longitudinal curative effect monitoring can be realized, the method is independent of tissue biopsy and is not influenced by tumor heterogeneity, the cost is reduced, and application is facilitated; meanwhile, peripheral blood not only objectively reflects the systematic immune state of a host, but also is closely related to tumor immunity as an important ring in a tumor immune cycle, and in the aspect of accuracy, the efficiency of a prediction model constructed by GPC reaches 0.886 and is remarkably higher than that of PDL1.

The invention discloses stomach wall tissue biopsy forceps under a laparoscope, and belongs to the technical field of medical instruments. The biopsy forceps aim at solving the problems that existing biopsy forceps are low in sampling efficiency and inconvenient in angle adjustment. The device comprises a fixed pipe and a rotating pipe, a first pull rod is slidably connected into the fixed pipe, a second pull rod is slidably connected into the rotating pipe, an extension column is integrally formed at one end of the second pull rod, a limiting ball is integrally formed at one end of the extension column, and a limiting groove matched with the extension column and the limiting ball is formed in one end of the first pull rod; a connecting part is arranged between the fixed pipe and the rotating pipe and is used for connecting the fixed pipe and the rotating pipe; biopsy forceps are installed at the end, away from the fixed tube, of the rotating tube, and the biopsy forceps and the rotating tube rotate through a connecting part. The driving part is arranged at one end of the fixing tube and used for driving the first pull rod to move, a plurality of samples can be taken through one-time insertion, angle adjustment is flexible, operation is labor-saving, and the device is used for stomach wall tissue sampling under a laparoscope.

The utility model relates to the field of temporary storage devices, in particular to a pathological tissue biopsy temporary storage device. The utility model provides a pathological tissue biopsy temporary storage device which can eject pathological tissues out of a temporary storage cylinder and is convenient for workers to take. A pathological tissue biopsy temporary storage device comprises a temporary storage barrel, a first spring, a mounting frame and a storing and taking mechanism, the middle of the temporary storage barrel is slidably and rotatably connected with the mounting frame, the first spring is connected between the mounting frame and the temporary storage barrel through a gasket, and the storing and taking mechanism capable of fixing and rapidly taking pathological tissues is arranged on the mounting frame. When diseased tissue needs to be taken out, the limiting piece is pulled to move to be separated from the upper portion of the mounting frame, so that the first spring rebounds, the mounting frame is driven to move upwards, the diseased tissue moves upwards, and the effects that the diseased tissue can be ejected out of the temporary storage barrel, and workers can take the diseased tissue conveniently are achieved.

The invention relates to an application of maximum allele mutation abundance in prediction of a mismatch repair protein complete metastatic colorectal cancer immunotherapy effect. The invention particularly relates to application of the maximum allele mutation abundance and a reagent or system for detecting the maximum allele mutation abundance in preparation of a system for predicting the immunotherapy effect of the mismatch repair protein complete metastatic colorectal cancer. According to the method, the baseline ctDNA maxVAF is used as the immunotherapy curative effect prediction marker for the first time, the blank in the field is filled, clinical individualized treatment, use of a peripheral blood sample and calculation of the maximum allele mutation abundance of peripheral blood circulation are better guided, sample acquisition is convenient, invasive tissue biopsy is not needed, and patient acceptance is high.

Methods are provided for detecting gene deletions and driver mutations using tumor-specific methylation patterns from cell-free DNA and tissue biopsies. The methods exploit the mutual exclusivity between tumor-specific methylation and homozygous gene deletion, enabling detection through absence of expected methylation signals. Applications include detection of MTAP, PTEN, and RB1 deletions, as well as prediction of EGFR single nucleotide (SNV) and small (up to 50 base pair) insertions and deletions (indel) driver mutations, enabling identification of patients eligible for targeted therapies.

A novel portable, and attachable device allows precise positioning of micro-tissues, tumor spheroids, and other biological samples during bioprinting. The device features an interchangeable connector for handling samples of various sizes and uses a manually adjustable pressure system for suction and deposition. A programmable control unit coordinates pressure and positioning based on input commands, enhancing accuracy and consistency in tissue handling. Compatible with multiple bioprinter systems and supporting both manual and automated operation, it streamlines workflows and improves user experience. This device addresses challenges in high-throughput biological positioning, critical for tissue engineering, clinical, pharmaceutical, and research applications. It supports advancements in customized medicine, biological models, and environmental monitoring, meeting the growing demand for precise biologic handling in the multi-billion-dollar bioprinting and biopsy markets. The device offers superior control over tissue biopsy positioning compared to current manual devices reliant on operator skill.

Methods for determining genomic variant clonality using multi-region sequencing assays and algorithms are described. For example, the methods can include receiving, at one or more processors, sequence read data for a sample obtained from a subject. The sequence read data is obtained from nucleic acid molecules (extracted, e.g., via needle punch) from a plurality of target regions within the sample (e.g., spatially distinct regions of a tissue biopsy sample). For each target region within the sample, a set of reads from the sequence read data associated with the respective target region is identified, then a presence of a candidate genomic variant within the target region is detected based on the set of reads. A total number of target regions in which the presence of the candidate genomic variant is compared to a first predetermined threshold. Based on the comparison, clonality of the candidate genomic variant is determined.

The invention relates to a non-invasive vagina examination treatment device which comprises a handheld shell, a visual collection tube, a control bin and a flushing sleeve, an end mounting seat is arranged at the working end of the visual collection tube, a picture collection camera is arranged in the end mounting seat, an LED annular lamp is arranged on the peripheral side of the picture collection camera, and the LED annular lamp is connected with the visual collection tube. A flushing interlayer is formed between the flushing sleeve and the visual collection tube, and one of a secretion extraction assembly, a tissue biopsy extraction assembly, a foreign matter clamping assembly and a negative pressure suction assembly is arranged at the working end of the visual collection tube. The visual collection tube enters the vagina from the vaginal orifice of a patient to achieve real-time collection of images in the vagina, different operation assemblies are installed at the front end of the visual collection tube in a matched mode, secretion extraction, tissue biopsy extraction, foreign matter clamping and other operations are achieved, the diameter of the whole device does not exceed 0.7 cm, and the visual collection tube is used for collecting the images in the vagina. The principle of minimum invasion can be met as much as possible, and the discomfort of a patient is effectively reduced.

The application discloses a low-noise pneumatic air gun type biopsy needle convenient for single-hand loading, which comprises an inner needle, an outer needle, a connector, a mechanical valve, a firing mechanism, a loading mechanism, a needle cylinder, a needle cylinder shell, a first piston, a tension spring, a second piston and a compression spring. The inner needle is glued on the outer side of the front end of the needle cylinder, the outer needle is glued on one end of the connector and is sleeved on the outer side of the inner needle, and the other end of the connector is fixed with the elongated part of the second piston. The needle cylinder comprises a needle cylinder part one and a needle cylinder part two, and the needle cylinder and the needle cylinder shell are bonded into an integrated whole after being aligned. The second piston is fixedly connected with the compression spring and is located on the inner side of the front end of the needle cylinder, and the other end of the compression spring is sleeved on the protruding part on the inner side of the front end of the needle cylinder. The first piston is fixedly connected with the tension spring and is located on the inner side of the tail end of the needle cylinder, and the other end of the tension spring is bonded with the tail seat of the needle cylinder. The firing mechanism realizes button control of cutting and sampling of the outer needle. The loading mechanism realizes button control of returning and loading of the outer needle. The application reduces the dependence of surgical operation on the experience of doctors, reduces the noise generated in the surgical process, avoids the body displacement of patients due to the noise, improves the precision of tissue biopsy surgery, can realize single-hand operation and improves the convenience of surgical operation.

The invention relates to the technical field of biological medicine, in particular to application of an lnc81 related reagent in ovarian function impairment related products. The invention provides an application of an lnc81 related reagent in ovarian function impairment related products, and provides a new biomarker for detecting ovarian function impairment, the biomarker is lnc81, and by using the marker, the false positive risk can be reduced, the detection accuracy is improved, the trauma of tissue biopsy is avoided, and the risk of ovarian function impairment is reduced. The method is suitable for dynamically monitoring curative effect or relapse.

Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.

The invention relates to devices and methods for depth-selective tissue biopsy and segregation, tubular stricture dilation, mucosal ablation and resurfacing, and clinical agent administration using balloon devices, including devices for selective access to different depths of a target tissue.

The invention relates to the field of medical treatment, in particular to a multifunctional tumor tissue biopsy sampler which comprises a shell, an inner sleeve is fixedly welded in the shell, a cavity is formed in the inner sleeve and filled with glycerol, and a sampling mechanism capable of cutting and sampling tumor tissue is fixedly mounted between the inner sleeve and the shell. A detection mechanism capable of detecting a sampled sample is fixedly installed between the upper end of the shell and the inner wall of the inner sleeve, two handles are fixedly connected to the outer wall of the shell through bolts, glycerin penetrates through a circular ring opening, a matching ring abuts against the inner wall of the circular ring opening after a movable circular ring stops, and the movable circular ring is reset after sampling. The movable sleeve is pushed by glycerol to slowly move upwards, the observation piece is driven by the pull rope to lengthen the corrugated sleeve, the tumor tissue is adsorbed into the corrugated sleeve by negative pressure generated inside, and after the tumor tissue is soaked in a 1% methylrosanilinium solution, medical staff can quickly judge whether the sample contains a tumor cell dense area or not according to the staining difference on the surface of the tissue, so that the diagnosis time is shortened.

The present disclosure relates generally to the field of medical devices. In particular, the present disclosure relates to medical systems and methods configured to shield the sharpened distal end of needles, such as exchangeable biopsy needles. The biopsy needles may be used for tissue biopsy and sampling under radial ultrasound guidance.

The invention discloses a kit for detecting circulating tumor DNA (deoxyribonucleic acid) of portal vein and branch vein blood of portal vein. The kit comprises: a nucleic acid extraction assembly comprising an optimized lysate and selectively bound magnetic beads; the library construction component comprises a terminal repair / tailing fusion enzyme and a Y-shaped linker with a molecular identifier; the targeted enrichment assembly comprises a specific primer group and a probe group and is used for enriching related gene targets of the abdominal organ tumors; and necessary reaction components. Through an optimized nucleic acid extraction method, an efficient library construction system and a precise targeted enrichment technology, high-sensitivity detection of low-abundance ctDNA in portal venous blood is achieved, and the lower detection limit reaches 0.1% of mutation allele frequency. The kit is particularly suitable for early diagnosis, curative effect monitoring and prognosis evaluation of abdominal organ tumors such as intestinal cancer, liver cancer and pancreatic cancer.

The application discloses a kind of methylation liquid biopsy model construction method and system of tuberculous granuloma and lung cancer based on multi-omics sequencing.Use the DNA and RNA data extracted from ex vivo lung tissue sample sequencing and combine blood data screening analysis to obtain methylation DNA data, then use machine learning classification model independent training to obtain methylation liquid biopsy model;System contains gene extraction equipment, second-generation high-throughput sequencer, blood testing equipment and computer, computer will be off data and blood data together into computer comprehensive screening to obtain methylation DNA data, then construct model and predict to obtain the biopsy result of tuberculous granuloma and lung cancer.The application can realize the high-precision, non-invasive detection of tuberculous granuloma and lung cancer, can be flexibly selected according to specific needs, has the stability and reliability characteristics of marker, avoids the invasive risk of tissue biopsy, has wide applicability, and has important application value.

The invention relates to the field of medical technical equipment, in particular to a puncture needle for muscular tissue biopsy, and aims to solve the problem that an existing device cannot meet the requirements of transverse and longitudinal puncture paths at the same time, the puncture needle comprises a needle shell, and further comprises a longitudinal sampling mechanism and a transverse sampling mechanism; the longitudinal sampling mechanism is slidably arranged at one end of the needle shell and used for obtaining tissue samples in the needle entering direction. The transverse sampling mechanism is movably arranged in the radial direction of the needle shell, and one end of the transverse sampling mechanism penetrates through the needle shell and is used for obtaining tissue samples in the direction perpendicular to the needle entering direction. Longitudinal sampling and transverse sampling can be achieved at the same time in the one-time puncture process of a diseased region, multi-point sampling is needed in some diseased regions due to heterogeneity, complex conditions of the diseased regions can be reflected more comprehensively, meanwhile, the puncture frequency is reduced, and discomfort of a patient is reduced. The transverse sampling enables the detection of the sample to be more comprehensive and three-dimensional, and the accuracy and reliability of tissue biopsy are further improved.

The present application relates to the field of medicine biotechnology, especially the application of RUNX2 as a marker in the preparation of a breast malignant phyllodes tumor diagnosis or detection reagent. The reagent can assist conventional biopsy according to the expression level of RUNX2 in different grades of breast phyllodes tumor, and can diagnose, differentially diagnose, grade and prognostically analyze the breast phyllodes tumor. The RUNX2 detection primer sequence and detection antibody of the present application are important components of the diagnosis or detection reagent or kit, so that the detection of breast malignant phyllodes tumor is more simple, fast and accurate, has good clinical application value, helps to further improve the diagnosis level of breast malignant phyllodes tumor, and is expected to become the first diagnosis and detection kit for breast malignant phyllodes tumor.

The invention belongs to the technical field of biological medicine, and particularly relates to a small cell lung cancer prognostic marker and application thereof. The molecular characteristics of blood sample proteins of small cell lung cancer patients are researched through a DIA analysis technology, and a small cell lung cancer serum protein expression difference atlas is drawn. The biomarker disclosed by the invention is simple and convenient to sample, the sample size required for detection is small, resources are saved, the serum B4GALT1 serving as a secretory marker of SCLC is easier to obtain compared with tissue biopsy, and the sensitivity is higher: the AUC of the B4GALT1 is 0.995, and the sensitivity and the specificity of the B4GALT1 are 1 and 0.95833 respectively.

1. The name of the design product: electric bone tissue biopsy push handle. 2. The use of the design product: for electric bone tissue biopsy push handle. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view.

The invention provides a system and a method for prospectively predicting the property of a thyroid nodule. The method comprises the following steps: an acquisition module is used for acquiring a tissue biopsy sample; the quantitative polymerase chain reaction detection module is used for detecting BRAF V600E information; the MRM MS detection module is used for detecting quantitative information of the peptide fragment; and the evaluation module is used for evaluating the property of the thyroid nodule by using a model for predicting the property of the thyroid nodule by taking the quantitative information of the final characteristic peptide fragment, the BRAF V600E information and the gender and age of the target subject as characteristic information. BRAF V600E mutation and the content of various polypeptides in a thyroid puncture sample are detected, the optimal feature combination is selected by using various machine learning means in combination with clinical information of gender, age and nodule size under ultrasound, a prediction model is established, the properties of thyroid nodules are evaluated and classified, clinicians are assisted in discriminating the thyroid nodules, and the accuracy of thyroid nodule identification is improved. Therefore, the problem of inaccurate diagnosis in clinic is relieved.

The present disclosure discusses a devices, systems and methods for transvascular, transvenous and / or transdural access, to the brain parenchyma, subarachnoid or subdural spaces. In some embodiments, the disclosed systems and methods may be used for local drug delivery, tissue biopsy, nanofluidic or microelectronic device / component delivery / insertion / implantation, in situ imaging, ablation of abnormal brain tissue and the like. Embodiments of the present disclosure include an access catheter system for extravascular procedures in the brain having an elongate, flexible tubular body, with at least one lumen extending axially there through between a proximal end, and a distal end. The access catheter system may include a side exit port and a distal end port. Further, the access catheter system may include a selective deflector positioned within the lumen configured to deflect a procedure catheter and permit a guide catheter.

A biopsy device for marking a location of a tissue biopsy, the biopsy device including: a needle having a needle body and a needle tip movably coupled to the needle body, a cutting apparatus disposed within the needle body, and a marker. The needle tip defines an open lumen. The marker is positioned within the open lumen. The marker includes a marker pellet. The needle tip is movable between a undeployed position and a deployed position in which the needle tip is positioned closer to the cutting apparatus than in the undeployed position such that the cutting apparatus interacts with the marker to push the marker pellet through the open lumen.

A core-severing cannula for use with tissue biopsy devices, comprising a plurality of flexible fingers for severing a tissue core. The core-severing cannula is positioned coaxially outside of a core-cutting cannula, and is slidable relative to the core-cutting cannula. As the device is activated, the core cutting cannula and core-severing cannula advance together to cut a core of tissue. Subsequently, the core-severing cannula is advanced relative to the core cutting cannula, and the fingers of the core-severing cannula assume a closed position to sever the core from the target site.

The combination of a marker system with binocular AR glasses to create a soft tissue procedure system used for surgery, biopsies, etc. A marker localization system is functionally integrated with augmented reality (AR) glasses. This soft tissue system can be applicable for AR surgeries in soft tissues involving mobile and static anatomies anywhere in the body, such as for example, breast, soft tissue, lungs, lymph nodes, liver surgeries, etc. By the placement of single or multiple markers and localizing the markers with a locator, such as a hand-held locator as a non-limiting example, the above-mentioned system provides a real-time intraoperative coordinate frame for the virtual projection of the markers (and the associated ROI) on / in the surgical field / biopsy field of view, using commercial off-the-shelf computer hardware (laptops, tablets, etc.) for the required image processing.

The present invention relates to a gene panel for predicting the responsiveness of renal cancer patients to radiotherapy. In the present invention, the responsiveness of patients to stereotactic body radiotherapy can be predicted with high accuracy by only biopsy of a small amount of tissue, thereby maximizing the efficiency of radiotherapy for patients with difficulty in surgery and at the same time, providing the advantage of preserving renal function.

The invention discloses a tumor immunotherapy curative effect prediction kit based on bone marrow spleen neutrophil proportion, which comprises an anti-human CD62L-PE antibody, an anti-human CD11b-PE-Cy7 antibody, an anti-human CD44-APC antibody and an anti-human ICAM1-FITC antibody which are respectively used for marking neutrophil subgroups in a peripheral blood sample, and comprises a hemolytic agent which is used for removing red blood cells in the sample, according to the present invention, the structure is scientific and reasonable, the use is safe and convenient, the ratio of the bone marrow-derived neutrophil to the spleen-derived neutrophil, i.e. The M / S ratio, has the significant negative correlation with the treatment effect of the PD-1 inhibitor, and the kit designed based on the discovery can achieve the rapid and non-invasive immune response evaluation at the peripheral blood level, compared with an existing method depending on tissue biopsy or PD-L1 immunohistochemistry, the method has the advantages that the immune microenvironment state of a patient can be reflected more early and dynamically, and a precise curative effect prediction basis is provided for a PD-1 / PD-L1 inhibitor and a combination therapy thereof.

The invention discloses a multi-parameter conjoint analysis method for early cancer screening and application of the multi-parameter conjoint analysis method, and relates to the technical field of cancer screening. The method comprises the following steps: firstly, acquiring a biological sample of a subject, wherein the biological sample comprises at least one of blood, urine and a tissue biopsy sample; then, the obtained biological sample is pretreated, and impurities in the sample are removed; according to the multi-parameter conjoint analysis method for early cancer screening, multiple biological samples are collected, multiple biological parameters are obtained through multiple detection technologies, and the accuracy and reliability of early cancer screening are improved; compared with the prior art, limitation of single parameter detection is avoided, the defects of a traditional multi-parameter joint analysis method are overcome, and whether a subject has early cancer lesion or not can be more accurately judged in practical application. The application of the method can realize early discovery and intervention of cancers, improves the survival rate of cancer patients, and has important clinical application value and social significance.